- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Merck Ratings Report.
Without further ado, here's a look at this week's Rocket Stocks.
These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.
Jim Cramer ponders what motivates someone to call a market top, and talks about how the market could be playing 'The Price Is Wrong.'
In a regulatory filing, Merck said it had determined on Feb. 17 that it will book an impairment charge in connection with the research program for MK-3682.